NASDAQ
8.37USD
-0.30 (-3.46%)
We have scored 9 news catalysts on Phathom Pharmaceuticals, Inc. (PHAT) over the past 12 months. The biggest single-day move next to one of them came Jan 7, 2026, when PHAT closed +10.4%: “Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants”. Coverage across the window leans positive (average ticker sentiment +0.28). Most of the impact sits in revenue growth rate and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
677.1M
P/E
—
EPS
—
Beta
0.51
52W range
8.21-18.31
Day range
8.29–8.53
Open
8.47
Prev close
8.67
Volume
1.1M
Avg volume
1.2M
Dividend
0.00
IPO
2019-10-25
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Phathom Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PHAT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
